Shares of RAPT Therapeutics Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company, surged over 60% to $1.39 in premarket trading after announcing an exclusive license agreement with Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group, for JYB1904/RPT904.
RPT904 is a novel, long-acting anti-IgE monoclonal antibody aimed at treating food allergies, chronic spontaneous urticaria (CSU), and other allergic inflammatory diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com